OB:ATEAIT
Atea Pharmaceuticals (AVIR): Assessing Valuation After C-BEYOND Phase 3 Enrollment Milestone and 2026 Data Timeline
Atea Pharmaceuticals has finished enrolling patients in its C-BEYOND Phase 3 trial for a new hepatitis C regimen, a key pipeline milestone that puts the program on a clear timeline toward mid 2026 topline data.
See our latest analysis for Atea.
The latest clinical milestone comes after a steady year for investors, with a roughly 10 percent year to date share price return and a strong 3 year total shareholder return of about 59 percent. This signals that momentum is gradually building rather...